Clinical Advisor6h
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.
Healio4d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Rheumatology Advisor6d
FDA Approves Cortrophin Gel in Prefilled Syringe Presentation
The FDA has approved Purified Cortrophin Gel (repository corticotropin injection USP) in a prefilled syringe presentation.
MarketWatch1d
S&P MidCap 400
Carpenter Technology Corp. $195.23 11.42 6.21% ...